Oculopharyngodistal Myopathy

1. Disease Information

Disease Definition and Overview

Oculopharyngodistal myopathy (OPDM; OMIM: 164310) is a rare adult-onset hereditary neuromuscular disorder characterized by progressive weakness affecting the ocular, pharyngeal, facial, and distal limb muscles (deng2020expansionofggc pages 1-2, ogasawara2020cggexpansionin pages 1-2, wagner2018mappingthechromosomal pages 1-6). The disease was first described by Satoyoshi and Kinoshita in 1977 as an autosomal dominant muscle condition with onset in late adulthood (wagner2018mappingthechromosomal pages 1-6). As stated in Deng et al. (2020), "Oculopharyngodistal myopathy (OPDM [MIM: 164310]) is a rare adult-onset myopathy with putative autosomal-dominant or autosomal-recessive inheritance. The typical clinical manifestations are insidiously progressive ptosis, ophthalmoparesis, facial and masseter weakness, dysphagia, and muscle weakness of distal limbs" (deng2020expansionofggc pages 1-2).

Key Identifiers

• OMIM ID: 164310
• MONDO ID: Not explicitly provided in retrieved literature
• Category: Mendelian, autosomal dominant (with variable penetrance)
• Alternative names: OPDM, Oculopharyngeal distal myopathy

Synonyms and Related Conditions

The disease spectrum now includes: - OPDM type 1 (OPDM1) - LRP12-associated - OPDM type 2 (OPDM2) - GIPC1-associated
- OPDM type 3 (OPDM3) - NOTCH2NLC-associated - OPDM type 4 (OPDM4) - RILPL1-associated - OPDM type 5 (OPDM5) - ABCD3-associated - Oculopharyngeal myopathy with leukoencephalopathy (OPML) - LOC642361/NUTM2B-AS1-associated

The condition is part of the "FNOP spectrum disorder" (Fragile X-associated tremor/ataxia syndrome, Neuronal intranuclear inclusion disease, and Oculopharyngodistal myopathy), reflecting shared CGG repeat pathogenesis (ishiura2023recentadvancesin pages 1-2, ishiura2023recentadvancesin pages 2-3).

Data Source Type

Information is derived from both patient-level clinical series and aggregated disease-level resources including genetic studies, histopathological analyses, and mechanistic investigations.

2. Etiology

Disease Causal Factors (Genetic)

OPDM is caused by CGG/GGC trinucleotide repeat expansions in the 5'-untranslated regions (5'UTR) of multiple genes. As of 2026, six causative genes have been identified (deng2020expansionofggc pages 1-2, boivin2026ggcrepeatexpansions pages 1-2, eura2026pathogeniccggexpansions pages 1-2):

Table: This table summarizes the currently recognized genetic subtypes linked to oculopharyngodistal myopathy and related OPML, including genes, repeat classes, reported size ranges, and major clinical distinctions. It is useful for comparing the expanding repeat-expansion spectrum and highlighting where evidence remains incomplete in the retrieved literature.

Summary of genetic subtypes is provided in the table above. The expanded GGC repeats are essential in pathogenesis regardless of the specific gene location (deng2020expansionofggc pages 1-2).

Risk Factors

Genetic Risk Factors: - CGG repeat length: Generally, pathogenic expansions exceed ~85-100 repeats depending on the gene, with most LRP12 patients having 125-150 repeats and NOTCH2NLC patients often having >100 repeats (deng2020expansionofggc pages 1-2, ogasawara2020cggexpansionin pages 1-2) - Somatic mosaicism: Intra-patient repeat size variability, particularly in LRP12 and NOTCH2NLC, may influence disease severity and progression (eura2025complexassociationsof pages 1-5) - Founder effects: Distinct single nucleotide variant patterns suggest founder haplotypes for LRP12 and GIPC1 expansions, indicating population-specific risk (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2) - Intermediate repeat expansions: Shorter LRP12 expansions (<100 repeats, mean ~76) have been associated with motor neuron disease/ALS phenotypes rather than classic OPDM (hobara2025linkinglrp12cgg pages 1-2)

Epigenetic Modifiers: - CpG methylation status: Higher methylation of expanded repeat regions, particularly in LRP12, is associated with delayed disease onset and can result in asymptomatic carriers despite extensive repeat expansions (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2). As described by Eura et al. (2025), "some asymptomatic carriers exhibit extensive repeat expansions, with hypermethylation of the expanded regions, suggesting that epigenetic modifications, such as promoter hypermethylation, may prevent disease development" (eura2025complexassociationsof pages 1-5).

Environmental Risk Factors: Not applicable - OPDM is a genetic disorder with no established environmental triggers.

Protective Factors

• Hypermethylation of expanded CGG repeats may act as a protective factor, preventing or delaying disease manifestation in some carriers (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)

Gene-Environment Interactions

Not established in the literature retrieved.

3. Phenotypes

Core Clinical Features

Table: This table summarizes core and variable clinical manifestations reported for oculopharyngodistal myopathy, including suggested HPO terms, approximate frequencies where available, onset patterns, severity, progression, and affected systems. It is useful for phenotype curation and knowledge-base annotation across genetically heterogeneous OPDM subtypes.

The comprehensive phenotype table above summarizes all clinical manifestations with HPO term suggestions and detailed characteristics.

Core OPDM Phenotype: The hallmark features include: 1. Ptosis (HP:0000508): Progressive drooping of eyelids 2. External ophthalmoplegia (HP:0000602): Paralysis of extraocular muscles 3. Dysphagia (HP:0002015): Difficulty swallowing 4. Dysarthria (HP:0001260): Impaired speech articulation 5. Facial weakness (HP:0000297): Weakness of facial muscles 6. Distal limb weakness (HP:0002460): Predominantly distal muscle weakness, distinguishing OPDM from the more proximally-affected OPMD

As stated in Ogasawara et al. (2020), "Oculopharyngodistal myopathy (OPDM) is a rare hereditary muscle disease characterized by progressive distal limb weakness, ptosis, ophthalmoplegia, bulbar muscle weakness and rimmed vacuoles on muscle biopsy" (ogasawara2020cggexpansionin pages 1-2).

Variable Neurological Features

Particularly in OPDM3 (NOTCH2NLC-associated), additional features may include: - Peripheral neuropathy (HP:0009830) - Cerebellar ataxia (HP:0001251) - Tremor (HP:0001337) - Leukoencephalopathy (HP:0002352) - Cognitive impairment (HP:0100543) - Retinopathy (HP:0000505) - Hearing impairment (HP:0000365)

In the NOTCH2NLC series, all seven patients demonstrated ptosis, ophthalmoplegia, dysarthria, and muscle weakness, with additional central and/or peripheral nervous system involvement (ogasawara2020cggexpansionin pages 1-2, ogasawara2020cggexpansionin pages 2-4).

Histopathological Phenotype

Muscle Biopsy Findings: - Rimmed vacuoles (HP:0012115): Hallmark pathology across all OPDM subtypes - Intranuclear inclusions (HP:0034335): p62/ubiquitin/SUMO1-positive inclusions in myonuclei and non-muscle cells (blood vessels, peripheral nerve bundles, muscle spindles) - Small angular fibers and internal nuclei: Indicating myopathic changes - Eosinophilic inclusions: Particularly noted in NOTCH2NLC cases

A key diagnostic feature differentiating OPDM from oculopharyngeal muscular dystrophy (OPMD) is the pattern of intranuclear inclusions. As Ogasawara et al. (2022) state: "OPMD can be differentiated from OPDM and other RVMs by the frequent presence of myo-INIs; and in OPDM, the presence of non-muscle-INIs in muscle pathology should be a diagnostic hallmark" (ogasawara2022intranuclearinclusionsin pages 1-2).

Age of Onset and Progression

• Typical age of onset: Adult-onset, predominantly in the 40s-50s (range: 1-68 years reported)
• Onset pattern: Insidious, slowly progressive
• Progression: All cases show progressive deterioration over time
• Disease course: Chronic, lifelong, progressive

Quality of Life Impact

While specific quality-of-life metrics were not extensively reported in the retrieved literature, the progressive nature of dysphagia, ophthalmoplegia, and limb weakness significantly impacts activities of daily living, swallowing safety, mobility, and independence.

4. Genetic/Molecular Information

Causal Genes

Six genes are currently implicated in OPDM/OPML:

1. LRP12 (HGNC:6700): Low-density lipoprotein receptor-related protein 12, chromosome 8q24.3
2. GIPC1 (HGNC:4270): GIPC PDZ domain containing family member 1, chromosome 19p13.3
3. NOTCH2NLC (HGNC:24993): Notch homolog 2 N-terminal like C, chromosome 1q21.2
4. RILPL1 (HGNC:10060): Rab interacting lysosomal protein like 1, chromosome 12q24.31
5. LOC642361/NUTM2B-AS1: Long noncoding RNA, chromosome 10q22.3
6. ABCD3 (HGNC:67): ATP binding cassette subfamily D member 3, chromosome 1p21.3

Pathogenic Variants

Variant Type: Noncoding CGG/GGC trinucleotide repeat expansions in 5'-untranslated regions

Variant Classification: Pathogenic according to established disease-causing repeat thresholds (varies by gene)

Normal vs. Pathogenic Repeat Ranges: - LRP12: Normal ~13-45 repeats; pathogenic ~85-289 repeats (most 125-150) - GIPC1: Pathogenic expansions identified; normal range not clearly established in retrieved texts - NOTCH2NLC: Pathogenic often >100 repeats; cases with 116-674 repeats reported - RILPL1, LOC642361, ABCD3: Pathogenic expansions confirmed; precise thresholds incompletely defined

Allele Frequency: OPDM is rare; population-specific screening suggests <1% of healthy controls carry expansions, but systematic population frequency data are limited (deng2020expansionofggc pages 1-2).

Somatic vs. Germline: Germline CGG expansions with somatic instability (intra-patient repeat size variability) documented (eura2025complexassociationsof pages 1-5).

Functional Consequences: The expanded repeats lead to dual mechanisms: 1. Protein gain-of-function: RAN (repeat-associated non-AUG) translation produces toxic polyglycine-containing proteins 2. RNA gain-of-function: Expanded CGG-repeat RNAs form toxic RNA foci

Modifier Genes

Not explicitly identified in retrieved literature, though epigenetic modifiers (methylation machinery) influence penetrance.

Epigenetic Information

DNA Methylation: CpG methylation of expanded repeat regions modulates disease expression. "A significant inverse correlation was observed between repeat length and age at onset in patients with GIPC1 or NOTCH2NLC expansions, while this was disturbed by higher methylation of expanded regions in patients with LRP12 expansions, leading to delayed onset" (eura2026pathogeniccggexpansions pages 1-2). Asymptomatic carriers with ultra-long, heavily methylated expansions have been documented (eura2025complexassociationsof pages 1-5).

Chromosomal Abnormalities

None beyond the repeat expansions. Structural variations flanking repeat regions have been identified in some patients (eura2025complexassociationsof pages 1-5).

5. Environmental Information

Environmental Factors

Not applicable - OPDM is a genetic disorder with no established environmental causative factors.

Lifestyle Factors

No specific lifestyle factors influence disease risk or progression in current literature.

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Table: This table summarizes the main pathogenic mechanisms proposed for oculopharyngodistal myopathy and links each mechanism to the evidence type, molecular players, affected cellular processes, and ontology suggestions. It is useful for curating pathophysiology across OPDM subtypes and distinguishing well-supported mechanisms from emerging ones.

The detailed pathophysiology table above summarizes all known mechanisms with ontology terms.

Primary Pathogenic Mechanisms

1. RAN Translation into Toxic Polyglycine Proteins

The most significant recent advancement in OPDM pathogenesis is the discovery that CGG/GGC repeat expansions are translated via repeat-associated non-AUG (RAN) translation into toxic polyglycine-containing proteins. As Boivin et al. (2026) state: "GGC repeat expansions causing oculopharyngodistal myopathy with or without oculopharyngeal myopathy leukoencephalopathy are located within previously unrecognized open reading frames (ORFs), resulting in their translation into new polyglycine-containing proteins" (boivin2026ggcrepeatexpansions pages 1-2).

Five distinct polyglycine proteins have been characterized: - uGIPpolyG (GIPC1-associated OPDM2) - uN2CpolyG (NOTCH2NLC-associated OPDM3/NIID)
- asRILpolyG (RILPL1-associated OPDM4) - LOC6polyG (LOC642361-associated OPML) - LRP12-associated polyG (LRP12-associated OPDM1)

These proteins: - Form p62/ubiquitin-positive cytoplasmic and intranuclear inclusions matching those seen in patient tissues (boivin2026ggcrepeatexpansions pages 1-2, li2026translationofexpanded pages 3-5, boivin2026ggcrepeatexpansions pages 5-6) - Cause cell death, myofiber atrophy, and neurodegeneration in cellular and animal models (boivin2026ggcrepeatexpansions pages 5-6, boivin2026ggcrepeatexpansions pages 7-8) - Show gene-specific differences in localization (e.g., asRILpolyG is more nuclear) and toxicity profiles (boivin2026ggcrepeatexpansions pages 5-6)

2. RNA Toxicity

Expanded CGG-repeat RNAs can sequester RNA-binding proteins (such as hnRNP A/B and MBNL1) and disrupt RNA metabolism, contributing to pathology (yu2021theggcrepeat pages 1-2, ishiura2023recentadvancesin pages 2-3).

3. Mitochondrial Dysfunction

A Drosophila model expressing uN2CpolyG demonstrated mitochondrial swelling, impaired oxidative phosphorylation, and energy deficits. These defects were also observed in muscle biopsies from individuals with NIID/NOTCH2NLC-related disease. Idebenone treatment restored mitochondrial function and alleviated neurodegenerative phenotypes in the fly model (yu2022cggrepeatexpansion pages 1-2).

4. Protein Aggregation and Proteostasis Failure

Polyglycine proteins aggregate into p62/ubiquitin/SUMO1-positive inclusions, overwhelming protein quality control systems. RNA-seq analysis implicated ubiquitin-mediated proteolysis, p53 signaling, and ribosome pathways (deng2020expansionofggc pages 1-2, deng2020expansionofggc pages 2-3).

5. Nuclear Architecture Disruption

LRP12-associated polyglycine inclusions disrupt the nuclear lamina (Lamin B1) architecture, impairing nuclear organization and nucleo-cytoplasmic homeostasis (li2026translationofexpanded pages 1-2, li2026translationofexpanded pages 3-5).

Cellular Processes Affected

• Protein translation (GO:0006412)
• Protein folding and quality control (GO:0034059)
• Autophagy and proteolysis (GO:0006914, GO:0010498)
• Mitochondrial oxidative phosphorylation (GO:0006119)
• RNA processing and metabolism (GO:0008380)
• Nuclear organization (GO:0006998)

Cell Types Involved

• Skeletal muscle fibers (CL:0000187): Primary site of pathology
• Neurons (CL:0000540): Affected in OPDM3/NIID and OPML subtypes
• Vascular endothelial cells: Contain intranuclear inclusions in OPDM
• Schwann cells/pericytes: Show pathology in nerve biopsies
• Muscle spindle-associated cells: Demonstrate inclusions

7. Anatomical Structures Affected

Organ Level

Primary Organs: - Skeletal muscle system (UBERON:0001015): Ocular (extraocular muscles), pharyngeal, facial, masseter, and distal limb muscles - Peripheral nervous system (UBERON:0000010): Especially in OPDM3, with demyelinating and axonal neuropathy - Central nervous system (UBERON:0001017): Variable involvement with leukoencephalopathy, ataxia, and cognitive changes in OPDM3/OPML

Secondary Organs: - Eye (UBERON:0000970): Retinopathy in some cases - Inner ear (UBERON:0002117): Hearing impairment - Heart (UBERON:0000948): Rare cardiac conduction abnormalities reported

Tissue and Cell Level

• Skeletal muscle tissue (UBERON:0001134): Rimmed vacuoles, myopathic changes, intranuclear inclusions
• Peripheral nerve tissue (UBERON:0002020): Neurogenic changes, intranuclear inclusions in non-myocyte cells
• White matter (UBERON:0002316): In OPML and OPDM3 with leukoencephalopathy

Subcellular Level

• Nucleus (GO:0005634): Intranuclear inclusions, disrupted nuclear lamina
• Cytoplasm (GO:0005737): Rimmed vacuoles, cytoplasmic inclusions
• Mitochondrion (GO:0005739): Swelling, dysfunction in oxidative phosphorylation

Localization

• Bilateral symmetric involvement is typical for extraocular and bulbar muscles
• Asymmetric muscle involvement on imaging reported in some cases (ogasawara2020cggexpansionin pages 2-4)
• Distal-predominant limb weakness distinguishes OPDM from OPMD

8. Temporal Development

Onset

• Typical age: Adult-onset, predominantly 40s-50s (range 1-68 years)
• Onset pattern: Insidious, slowly progressive over years to decades
• Mode of presentation: Variable - may begin with ptosis, dysphagia, or limb weakness depending on subtype

Progression

• Disease stages: Not formally staged, but progressive worsening of weakness
• Progression rate: Slow, over decades
• Disease course pattern: Progressive, chronic
• Disease duration: Lifelong, chronic condition

Patterns

• Remission: No spontaneous remissions documented
• Critical periods: Age-dependent onset influenced by repeat methylation status; earlier onset correlates with longer repeat lengths in GIPC1 and NOTCH2NLC (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)

9. Inheritance and Population

Epidemiology

• Prevalence: Rare disease; approximately 300 individuals reported worldwide as of recent reviews (deng2020expansionofggc pages 1-2, ishiura2023recentadvancesin pages 2-3)
• Incidence: Not established due to rarity
• Geographic distribution: Predominantly East Asian populations (Japan, China), with cases also reported from Thailand, Netherlands, Turkey, England, Italy, and other regions (deng2020expansionofggc pages 1-2, ishiura2023recentadvancesin pages 2-3)

For Genetic Etiology

Inheritance Pattern: Autosomal dominant with variable penetrance and incomplete penetrance noted (deng2020expansionofggc pages 1-2, eura2025complexassociationsof pages 1-5, ishiura2023recentadvancesin pages 2-3)

Penetrance: Incomplete; age-dependent with influence from repeat methylation status. Asymptomatic carriers with heavily methylated long repeats have been documented (eura2025complexassociationsof pages 1-5).

Expressivity: Variable; phenotypic spectrum ranges from isolated myopathy to multisystem neurodegeneration depending on affected gene

Genetic Anticipation: Not formally established, though somatic instability and intergenerational transmission warrant further study

Germline Mosaicism: Not explicitly documented in retrieved texts

Founder Effects: Distinct SNP haplotypes flanking LRP12 and GIPC1 expansions suggest founder effects in affected populations (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)

Consanguinity Role: Not a prominent feature given autosomal dominant inheritance

Carrier Frequency: Not systematically established; OPDM is rare

Population Demographics

Affected Populations: Predominantly Japanese and Chinese populations. "Most cases of OPDM were reported from Japan and China, whereas only 13 families were reported from other regions such as Thai, Netherlands, Turkey, England, and Italy until 2019" (ishiura2023recentadvancesin pages 2-3).

Sex Ratio: Both males and females affected; no clear sex predilection evident in case series (ogasawara2020cggexpansionin pages 2-4)

Age Distribution: Adult-onset disease; most patients symptomatic by 40s-60s

10. Diagnostics

Clinical Tests

Laboratory Tests: - Serum creatine kinase (CK): Elevated in most cases (range 63-1886 IU/L in one series), indicating muscle damage (ogasawara2020cggexpansionin pages 2-4) - CSF analysis: Generally normal or mildly elevated protein (60-157 mg/dL reported); cell count typically <10/µL (ogasawara2020cggexpansionin pages 2-4) - Lactate: Mildly elevated in some cases (9.7-21.6 mg/dL), potentially reflecting mitochondrial involvement (ogasawara2020cggexpansionin pages 2-4)

Biomarkers: - p62/SQSTM1-positive inclusions: Hallmark in muscle and other tissues - Polyglycine proteins: Recently developed antibodies can detect subtype-specific polyglycine proteins (uGIPpolyG, uN2CpolyG, asRILpolyG, LOC6polyG) in tissue inclusions (boivin2026ggcrepeatexpansions pages 1-2)

Imaging Studies: - Brain MRI: Diffusion-weighted imaging (DWI) hyperintensities at corticomedullary junctions, leukoencephalopathy, cerebellar/cerebral atrophy in OPDM3/OPML (ogasawara2020cggexpansionin pages 2-4, ishiura2023recentadvancesin pages 2-3) - Muscle MRI/CT: Asymmetric muscle atrophy and fat replacement, distal-predominant changes (ogasawara2020cggexpansionin pages 2-4)

Electrophysiology: - EMG: Myopathic changes (short-duration, low-amplitude motor unit potentials) - Nerve conduction studies: Slowed motor/sensory velocities or decreased amplitudes in cases with peripheral neuropathy (ogasawara2020cggexpansionin pages 2-4)

Muscle Biopsy: - Histochemistry: Rimmed vacuoles (modified Gomori trichrome), small angular fibers, internal nuclei, chronic myopathic changes - Immunohistochemistry: p62-positive intranuclear inclusions in myonuclei and non-muscle cells (blood vessels, nerve bundles, muscle spindles) - this pattern differentiates OPDM from OPMD (ogasawara2022intranuclearinclusionsin pages 1-2) - Electron microscopy: Intranuclear filamentous inclusions (10-18 nm diameter, distinct from OPMD's 8.5 nm) (ishiura2023recentadvancesin pages 2-3)

Skin Biopsy: - Can demonstrate intranuclear inclusions in NOTCH2NLC-associated cases (ogasawara2020cggexpansionin pages 2-4)

Genetic Testing

Recommended Approach: Targeted genetic testing for CGG/GGC repeat expansions in known OPDM genes

Methods: 1. Repeat-primed PCR (RP-PCR): Initial screening method for detecting expanded repeats (deng2020expansionofggc pages 1-2, ogasawara2020cggexpansionin pages 1-2) 2. Amplicon-length PCR (AL-PCR) / Fluorescence AL-PCR: Sizing of repeat expansions (deng2020expansionofggc pages 1-2, yu2021theggcrepeat pages 1-2) 3. Southern blotting: Confirmation and accurate sizing of large expansions (ogasawara2020cggexpansionin pages 1-2, yu2021theggcrepeat pages 1-2) 4. Long-read sequencing (Oxford Nanopore): Comprehensive repeat characterization, methylation analysis (deng2020expansionofggc pages 1-2, yu2021theggcrepeat pages 1-2) 5. CRISPR/Cas9-targeted nanopore sequencing (nCATS): Advanced method for simultaneous analysis of repeat length, flanking sequences, haplotypes, structural variation, and CpG methylation (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)

Gene Panels: Should include LRP12, GIPC1, NOTCH2NLC, RILPL1, LOC642361/NUTM2B-AS1, and ABCD3

Single Gene Testing: Appropriate when specific subtype suspected based on phenotype

Whole Exome/Genome Sequencing: May miss repeat expansions due to technical limitations; dedicated repeat-expansion methods required

Clinical Criteria

Diagnostic Criteria: OPDM is diagnosed based on: 1. Characteristic clinical features (ptosis, ophthalmoplegia, bulbar weakness, distal limb weakness) 2. Myopathological findings (rimmed vacuoles, intranuclear inclusions) 3. Genetic confirmation of CGG/GGC repeat expansion 4. Exclusion of OPMD (PABPN1 GCN expansion) and myotonic dystrophy (DMPK CTG expansion)

Differential Diagnosis: - Oculopharyngeal muscular dystrophy (OPMD): Distinguished by proximal>distal weakness, 8.5 nm intranuclear filaments, frequent myo-INIs (>5.9%), and PABPN1 GCN expansion. OPDM has non-muscle INIs and rare myo-INIs (<2.8%) (ogasawara2022intranuclearinclusionsin pages 1-2) - Myotonic dystrophy type 1: DMPK CTG expansion, myotonia - Mitochondrial myopathies: May have ptosis and ophthalmoplegia but distinct histology - Inclusion body myositis: Inflammatory myopathy with rimmed vacuoles but different clinical pattern

Screening

• Newborn screening: Not applicable
• Carrier screening: Not routine given rarity and incomplete penetrance
• Cascade screening: May be considered in families with identified pathogenic expansions

11. Outcome/Prognosis

Survival and Mortality

• Life expectancy: Not systematically studied; disease is progressive but not typically immediately life-threatening
• Mortality rate: No specific mortality data available in retrieved literature
• Disease-specific mortality: Complications from dysphagia (aspiration) and respiratory involvement may contribute to mortality

Morbidity and Function

• Morbidity: Progressive disability from muscle weakness, dysphagia, and visual impairment
• Disability outcomes: Increasing dependence for activities of daily living, mobility aids, feeding assistance
• Quality of life: Significantly impacted by dysphagia, ophthalmoplegia, and limb weakness

Disease Course

• Complications: Aspiration pneumonia from dysphagia, malnutrition, falls from muscle weakness, peripheral neuropathy complications
• Recovery potential: No recovery; progressive deterioration is the rule

Prediction

• Prognostic factors:
• Longer CGG repeats correlate with earlier onset in GIPC1 and NOTCH2NLC (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)
• Methylation status modifies onset in LRP12 (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2)
• NOTCH2NLC-associated cases may have more multisystem involvement (ogasawara2020cggexpansionin pages 2-4)
• Prognostic biomarkers: Repeat length and methylation status

12. Treatment

Pharmacotherapy

Currently, no disease-modifying pharmacological treatments are available for OPDM. Management is supportive and symptomatic.

Experimental Therapeutics: - Idebenone: Showed promise in a Drosophila model of NOTCH2NLC-related disease. "Idebenone treatment restored mitochondrial function and alleviated neurodegenerative phenotypes in transgenic flies" (yu2022cggrepeatexpansion pages 1-2). Clinical trials have not been reported. - TMPyP4 (cationic porphyrin): A 2026 study identified TMPyP4 as reducing polyglycine protein abundance and toxicity in cell cultures and animal models by targeting translation (boivin2026ggcrepeatexpansions pages 7-8). This represents a proof-of-concept therapeutic approach but is not yet in clinical use.

Advanced Therapeutics

• Gene therapy: Not developed for OPDM
• RNA-based therapies: Antisense oligonucleotides (ASOs) targeting expanded CGG-repeat RNAs are theoretically applicable but not yet developed for OPDM
• CRISPR-based approaches: Could theoretically target repeat expansions but not clinically available

Surgical and Interventional

• Ptosis surgery: May improve visual field
• Gastrostomy tube (PEG): For severe dysphagia to maintain nutrition and prevent aspiration
• Tracheostomy: May be required if respiratory muscles severely affected

Supportive and Rehabilitative

• Supportive care:
• Dysphagia management: Modified diet consistencies, speech-language pathology evaluation
• Nutritional support: Dietitian consultation
• Respiratory support: Monitoring of pulmonary function
• Rehabilitation:
• Physical therapy: Maintain mobility and prevent contractures
• Occupational therapy: Adaptive devices for activities of daily living
• Speech therapy: Swallowing exercises, communication strategies

Experimental

• Phase I/II trials: None identified in retrieved literature

Treatment Outcomes

No systematic treatment outcome data are available given the lack of disease-modifying therapies.

Treatment Strategy

Multidisciplinary Approach: - Neurology/neuromuscular specialist - Ophthalmology (for ptosis, ophthalmoplegia) - Speech-language pathology (dysphagia) - Physical and occupational therapy - Nutritional support - Genetic counseling

13. Prevention

Prevention Levels

• Primary prevention: Not applicable for genetic disease
• Secondary prevention: Early genetic diagnosis allows anticipatory guidance and symptomatic management
• Tertiary prevention: Management of dysphagia, prevention of aspiration pneumonia, fall prevention

Immunization

Not applicable.

Screening and Early Detection

• Genetic screening: Family members of affected individuals may consider predictive genetic testing
• Preimplantation genetic diagnosis (PGD): Theoretically possible for families with known pathogenic expansions
• Prenatal testing: Technically feasible but ethical considerations apply given adult onset and variable penetrance

Behavioral Interventions

Not applicable.

Counseling

Genetic counseling: Recommended for: - Affected individuals understanding inheritance and recurrence risk - At-risk family members considering predictive testing - Reproductive planning

Public Health

Not applicable for this rare genetic disorder.

Prophylaxis

Not applicable.

14. Other Species / Natural Disease

Taxonomy

No naturally occurring OPDM has been documented in other species.

Natural Disease

No spontaneous animal models identified in retrieved literature.

15. Model Organisms

Model Types

Drosophila melanogaster (Fruit Fly): A transgenic fly model expressing uN2CpolyG (NOTCH2NLC-associated polyglycine) was developed by Yu et al. (2022). The model recapitulates key disease features: - Progressive neuronal cell loss - Locomotor deficiency - Shortened lifespan
- Mitochondrial swelling and dysfunction - p62-positive inclusions

The fly model was used to identify idebenone as a therapeutic candidate targeting mitochondrial dysfunction (yu2022cggrepeatexpansion pages 1-2).

Mus musculus (Mouse): Mouse models have been generated using recombinant adeno-associated viral (rAAV) vectors to express polyglycine proteins in skeletal muscle and CNS: - Muscle-specific expression causes myofiber atrophy, centralized nuclei, p62-positive inclusions, and histological changes resembling human OPDM (boivin2026ggcrepeatexpansions pages 5-6, boivin2026ggcrepeatexpansions pages 7-8) - CNS expression causes progressive motor deficits, coordination changes, neuroinflammation, Purkinje cell loss, and reduced lifespan (boivin2026ggcrepeatexpansions pages 5-6, boivin2026ggcrepeatexpansions pages 7-8) - Different polyglycine proteins (uGIPpolyG, uN2CpolyG, LOC6polyG, asRILpolyG) show varying toxicity profiles, with LOC6polyG and uN2CpolyG showing more severe phenotypes than uGIPpolyG (boivin2026ggcrepeatexpansions pages 5-6, boivin2026ggcrepeatexpansions pages 7-8)

Genetic Models

• Transgenic: Fly and mouse models expressing polyglycine proteins under various promoters
• Viral transduction: rAAV-mediated delivery in mouse muscle and CNS

Model Characteristics

Phenotype Recapitulation: - Polyglycine protein aggregation and p62-positive inclusions: Yes - Muscle pathology (atrophy, centralized nuclei): Yes - Neurodegeneration: Yes - Mitochondrial dysfunction: Yes (fly model) - Progressive locomotor deficits: Yes

Model Limitations: - Do not fully capture the slowly progressive, decades-long human disease course - Single-gene models may not reflect genetic heterogeneity - Methylation-mediated modulation of phenotype not extensively modeled

Applications

• Mechanistic studies of polyglycine toxicity
• Testing of therapeutic candidates (idebenone, TMPyP4)
• Understanding mitochondrial involvement
• Dissecting cell-autonomous vs. non-autonomous pathology

Resources

• Drosophila models: Available through research groups (Yu, Deng, Wang laboratories)
• Mouse models: rAAV constructs and protocols described in recent publications

Summary and Key Insights

Oculopharyngodistal myopathy represents a genetically heterogeneous group of adult-onset myopathies caused by CGG/GGC trinucleotide repeat expansions in at least six different genes. Recent breakthroughs (2020-2026) have dramatically advanced our understanding:

1. Unified Molecular Mechanism: Despite genetic heterogeneity, all OPDM subtypes share a common pathogenic mechanism involving RAN translation of expanded CGG repeats into toxic polyglycine-containing proteins that aggregate and cause cellular dysfunction (boivin2026ggcrepeatexpansions pages 1-2, li2026translationofexpanded pages 3-5, boivin2026ggcrepeatexpansions pages 5-6).

2. Dual Pathogenesis: Both protein toxicity (polyglycine aggregates) and RNA toxicity (RNA foci) likely contribute to disease (ishiura2023recentadvancesin pages 2-3).

3. Epigenetic Modulation: CpG methylation of expanded repeats modulates penetrance and age of onset, explaining incomplete penetrance and asymptomatic carriers (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2).

4. Phenotypic Spectrum: While core myopathic features are shared, NOTCH2NLC-associated OPDM3 often includes multisystem neurological involvement, overlapping with NIID and forming part of the "FNOP spectrum" (ishiura2023recentadvancesin pages 1-2, ishiura2023recentadvancesin pages 2-3).

5. Diagnostic Advances: Long-read sequencing and CRISPR/Cas9-targeted approaches now enable comprehensive repeat characterization including length, methylation, and structural variation (eura2025complexassociationsof pages 1-5, eura2026pathogeniccggexpansions pages 1-2).

6. Therapeutic Prospects: Proof-of-concept therapeutics targeting polyglycine expression (TMPyP4) and mitochondrial function (idebenone) offer hope for future disease-modifying treatments (boivin2026ggcrepeatexpansions pages 7-8, yu2022cggrepeatexpansion pages 1-2).

This comprehensive report synthesizes current knowledge (2020-2026) on OPDM, providing a foundation for disease knowledge base curation, diagnostic algorithm development, and therapeutic research directions.

Note: This report prioritizes recent sources (2023-2026) while incorporating landmark earlier studies. All major claims are cited with PMIDs where available through the pqac citation system. The report is structured for direct use in populating a disease knowledge base with ontology terms, evidence items, and detailed annotations.

References

1. (deng2020expansionofggc pages 1-2): Jianwen Deng, Jiaxi Yu, Pidong Li, Xinghua Luan, Li Cao, Juan Zhao, Meng Yu, Wei Zhang, He Lv, Zhiying Xie, LingChao Meng, Yiming Zheng, Yawen Zhao, Qiang Gang, Qingqing Wang, Jing Liu, Min Zhu, Xueyu Guo, Yanan Su, Yu Liang, Fan Liang, Tomohiro Hayashi, Meiko Hashimoto Maeda, Tatsuro Sato, Shigehisa Ura, Yasushi Oya, Masashi Ogasawara, Aritoshi Iida, Ichizo Nishino, Chang Zhou, Chuanzhu Yan, Yun Yuan, Daojun Hong, and Zhaoxia Wang. Expansion of ggc repeat in gipc1 is associated with oculopharyngodistal myopathy. The American Journal of Human Genetics, 106:793-804, Jun 2020. URL: https://doi.org/10.1016/j.ajhg.2020.04.011, doi:10.1016/j.ajhg.2020.04.011. This article has 162 citations.

2. (ogasawara2020cggexpansionin pages 1-2): Masashi Ogasawara, Aritoshi Iida, Theerawat Kumutpongpanich, Ayami Ozaki, Yasushi Oya, Hirofumi Konishi, Akinori Nakamura, Ryuta Abe, Hiroshi Takai, Ritsuko Hanajima, Hiroshi Doi, Fumiaki Tanaka, Hisayoshi Nakamura, Ikuya Nonaka, Zhaoxia Wang, Shinichiro Hayashi, Satoru Noguchi, and Ichizo Nishino. Cgg expansion in notch2nlc is associated with oculopharyngodistal myopathy with neurological manifestations. Acta Neuropathologica Communications, Nov 2020. URL: https://doi.org/10.1186/s40478-020-01084-4, doi:10.1186/s40478-020-01084-4. This article has 122 citations and is from a peer-reviewed journal.

3. (wagner2018mappingthechromosomal pages 1-6): Matias Wagner. Mapping the chromosomal locus of oculopharyngodistal myopathy with microsatellite markers and next generation sequencing. Dissertation, Jan 2018. URL: https://doi.org/10.5282/edoc.22478, doi:10.5282/edoc.22478. This article has 0 citations.

4. (ishiura2023recentadvancesin pages 1-2): Hiroyuki Ishiura, Shoji Tsuji, and Tatsushi Toda. Recent advances in cgg repeat diseases and a proposal of fragile x-associated tremor/ataxia syndrome, neuronal intranuclear inclusion disease, and oculophryngodistal myopathy (fnop) spectrum disorder. Journal of Human Genetics, 68:169-174, Jan 2023. URL: https://doi.org/10.1038/s10038-022-01116-y, doi:10.1038/s10038-022-01116-y. This article has 26 citations and is from a peer-reviewed journal.

5. (ishiura2023recentadvancesin pages 2-3): Hiroyuki Ishiura, Shoji Tsuji, and Tatsushi Toda. Recent advances in cgg repeat diseases and a proposal of fragile x-associated tremor/ataxia syndrome, neuronal intranuclear inclusion disease, and oculophryngodistal myopathy (fnop) spectrum disorder. Journal of Human Genetics, 68:169-174, Jan 2023. URL: https://doi.org/10.1038/s10038-022-01116-y, doi:10.1038/s10038-022-01116-y. This article has 26 citations and is from a peer-reviewed journal.

6. (boivin2026ggcrepeatexpansions pages 1-2): Manon Boivin, Jiaxi Yu, Nobuyuki Eura, Léa Schmitt, David Pietri, Erwan Grandgirard, Patrice Goetz-Reiner, Damien Plassard, Chadia Nahy, Anne Maglott, Bastien Morlet, Chao Gao, Elise Lefebvre, Muriel Philipps, Pascal Eberling, Angélique Pichot, Paola Rossolillo, Christelle Thibault, Mustapha Oulad-Abdelghani, Ichizo Nishino, Kang Yang, Ning Wang, Zhaoxia Wang, Jianwen Deng, and Nicolas Charlet-Berguerand. Ggc repeat expansions within new open reading frames are translated into toxic polyglycine proteins in oculopharyngodistal myopathy. Nature Genetics, 58:517-529, Feb 2026. URL: https://doi.org/10.1038/s41588-026-02507-z, doi:10.1038/s41588-026-02507-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

7. (eura2026pathogeniccggexpansions pages 1-2): Nobuyuki Eura, Satoru Noguchi, Megumu Ogawa, Kyuto Sonehara, Ai Yamanaka, Takashi Kurashige, Shinichiro Hayashi, Yukinori Okada, Kazuma Sugie, and Ichizo Nishino. Pathogenic cgg expansions in oculopharyngodistal myopathy exhibit distinct characteristics of each causative gene on the flanking sequences as well as methylation status. Genome Medicine, Mar 2026. URL: https://doi.org/10.1186/s13073-026-01617-x, doi:10.1186/s13073-026-01617-x. This article has 0 citations and is from a highest quality peer-reviewed journal.

8. (li2026translationofexpanded pages 1-2): Chengcheng Li, Jil A. Daw, Sara K. Pittman, Connor J. Maltby, Hidetoshi Sakurai, Peter K. Todd, and Conrad C. Weihl. Translation of expanded cgg repeats in lrp12 associated oculopharyngodistal myopathy. Acta Neuropathologica Communications, Mar 2026. URL: https://doi.org/10.1186/s40478-026-02272-4, doi:10.1186/s40478-026-02272-4. This article has 1 citations and is from a peer-reviewed journal.

9. (hobara2025linkinglrp12cgg pages 1-2): Takahiro Hobara, Masahiro Ando, Yujiro Higuchi, Jun-Hui Yuan, Akiko Yoshimura, Fumikazu Kojima, Yutaka Noguchi, Jun Takei, Yu Hiramatsu, Satoshi Nozuma, Tomonori Nakamura, Tadashi Adachi, Keiko Toyooka, Toru Yamashita, Yusuke Sakiyama, Akihiro Hashiguchi, Eiji Matsuura, Yuji Okamoto, and Hiroshi Takashima. Linking lrp12 cgg repeat expansion to inherited peripheral neuropathy. Journal of Neurology, Neurosurgery & Psychiatry, 96:140-149, Jul 2025. URL: https://doi.org/10.1136/jnnp-2024-333403, doi:10.1136/jnnp-2024-333403. This article has 18 citations.

10. (deng2020expansionofggc pages 2-3): Jianwen Deng, Jiaxi Yu, Pidong Li, Xinghua Luan, Li Cao, Juan Zhao, Meng Yu, Wei Zhang, He Lv, Zhiying Xie, LingChao Meng, Yiming Zheng, Yawen Zhao, Qiang Gang, Qingqing Wang, Jing Liu, Min Zhu, Xueyu Guo, Yanan Su, Yu Liang, Fan Liang, Tomohiro Hayashi, Meiko Hashimoto Maeda, Tatsuro Sato, Shigehisa Ura, Yasushi Oya, Masashi Ogasawara, Aritoshi Iida, Ichizo Nishino, Chang Zhou, Chuanzhu Yan, Yun Yuan, Daojun Hong, and Zhaoxia Wang. Expansion of ggc repeat in gipc1 is associated with oculopharyngodistal myopathy. The American Journal of Human Genetics, 106:793-804, Jun 2020. URL: https://doi.org/10.1016/j.ajhg.2020.04.011, doi:10.1016/j.ajhg.2020.04.011. This article has 162 citations.

11. (boivin2026ggcrepeatexpansions pages 3-4): Manon Boivin, Jiaxi Yu, Nobuyuki Eura, Léa Schmitt, David Pietri, Erwan Grandgirard, Patrice Goetz-Reiner, Damien Plassard, Chadia Nahy, Anne Maglott, Bastien Morlet, Chao Gao, Elise Lefebvre, Muriel Philipps, Pascal Eberling, Angélique Pichot, Paola Rossolillo, Christelle Thibault, Mustapha Oulad-Abdelghani, Ichizo Nishino, Kang Yang, Ning Wang, Zhaoxia Wang, Jianwen Deng, and Nicolas Charlet-Berguerand. Ggc repeat expansions within new open reading frames are translated into toxic polyglycine proteins in oculopharyngodistal myopathy. Nature Genetics, 58:517-529, Feb 2026. URL: https://doi.org/10.1038/s41588-026-02507-z, doi:10.1038/s41588-026-02507-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

12. (ogasawara2020cggexpansionin pages 2-4): Masashi Ogasawara, Aritoshi Iida, Theerawat Kumutpongpanich, Ayami Ozaki, Yasushi Oya, Hirofumi Konishi, Akinori Nakamura, Ryuta Abe, Hiroshi Takai, Ritsuko Hanajima, Hiroshi Doi, Fumiaki Tanaka, Hisayoshi Nakamura, Ikuya Nonaka, Zhaoxia Wang, Shinichiro Hayashi, Satoru Noguchi, and Ichizo Nishino. Cgg expansion in notch2nlc is associated with oculopharyngodistal myopathy with neurological manifestations. Acta Neuropathologica Communications, Nov 2020. URL: https://doi.org/10.1186/s40478-020-01084-4, doi:10.1186/s40478-020-01084-4. This article has 122 citations and is from a peer-reviewed journal.

13. (ogasawara2022intranuclearinclusionsin pages 1-2): Masashi Ogasawara, Nobuyuki Eura, Aritoshi Iida, Theerawat Kumutpongpanich, Narihiro Minami, Ikuya Nonaka, Shinichiro Hayashi, Satoru Noguchi, and Ichizo Nishino. Intranuclear inclusions in muscle biopsy can differentiate oculopharyngodistal myopathy and oculopharyngeal muscular dystrophy. Acta Neuropathologica Communications, Dec 2022. URL: https://doi.org/10.1186/s40478-022-01482-w, doi:10.1186/s40478-022-01482-w. This article has 21 citations and is from a peer-reviewed journal.

14. (boivin2026ggcrepeatexpansions pages 5-6): Manon Boivin, Jiaxi Yu, Nobuyuki Eura, Léa Schmitt, David Pietri, Erwan Grandgirard, Patrice Goetz-Reiner, Damien Plassard, Chadia Nahy, Anne Maglott, Bastien Morlet, Chao Gao, Elise Lefebvre, Muriel Philipps, Pascal Eberling, Angélique Pichot, Paola Rossolillo, Christelle Thibault, Mustapha Oulad-Abdelghani, Ichizo Nishino, Kang Yang, Ning Wang, Zhaoxia Wang, Jianwen Deng, and Nicolas Charlet-Berguerand. Ggc repeat expansions within new open reading frames are translated into toxic polyglycine proteins in oculopharyngodistal myopathy. Nature Genetics, 58:517-529, Feb 2026. URL: https://doi.org/10.1038/s41588-026-02507-z, doi:10.1038/s41588-026-02507-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

15. (boivin2026ggcrepeatexpansions pages 7-8): Manon Boivin, Jiaxi Yu, Nobuyuki Eura, Léa Schmitt, David Pietri, Erwan Grandgirard, Patrice Goetz-Reiner, Damien Plassard, Chadia Nahy, Anne Maglott, Bastien Morlet, Chao Gao, Elise Lefebvre, Muriel Philipps, Pascal Eberling, Angélique Pichot, Paola Rossolillo, Christelle Thibault, Mustapha Oulad-Abdelghani, Ichizo Nishino, Kang Yang, Ning Wang, Zhaoxia Wang, Jianwen Deng, and Nicolas Charlet-Berguerand. Ggc repeat expansions within new open reading frames are translated into toxic polyglycine proteins in oculopharyngodistal myopathy. Nature Genetics, 58:517-529, Feb 2026. URL: https://doi.org/10.1038/s41588-026-02507-z, doi:10.1038/s41588-026-02507-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

16. (eura2025complexassociationsof pages 1-5): Nobuyuki Eura, Satoru Noguchi, Megumu Ogawa, Kyuto Sonehara, Ai Yamanaka, Shinichiro Hayashi, Yukinori Okada, Kazuma Sugie, and Ichizo Nishino. Complex associations of genetic/epigenetic variations of cgg repeats with patient phenotypes in oculopharyngodistal myopathy. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.13.25327490, doi:10.1101/2025.05.13.25327490. This article has 1 citations.

17. (yu2021theggcrepeat pages 1-2): Jiaxi Yu, Jianwen Deng, Xueyu Guo, Jingli Shan, Xinghua Luan, Li Cao, Juan Zhao, Meng Yu, Wei Zhang, He Lv, Zhiying Xie, LingChao Meng, Yiming Zheng, Yawen Zhao, Qiang Gang, Qingqing Wang, Jing Liu, Min Zhu, Binbin Zhou, Pidong Li, Yinzhe Liu, Yang Wang, Chuanzhu Yan, Daojun Hong, Yun Yuan, and Zhaoxia Wang. The ggc repeat expansion in notch2nlc is associated with oculopharyngodistal myopathy type 3. Brain, 144:1819-1832, Mar 2021. URL: https://doi.org/10.1093/brain/awab077, doi:10.1093/brain/awab077. This article has 143 citations and is from a highest quality peer-reviewed journal.

18. (li2026translationofexpanded pages 3-5): Chengcheng Li, Jil A. Daw, Sara K. Pittman, Connor J. Maltby, Hidetoshi Sakurai, Peter K. Todd, and Conrad C. Weihl. Translation of expanded cgg repeats in lrp12 associated oculopharyngodistal myopathy. Acta Neuropathologica Communications, Mar 2026. URL: https://doi.org/10.1186/s40478-026-02272-4, doi:10.1186/s40478-026-02272-4. This article has 1 citations and is from a peer-reviewed journal.

19. (yu2022cggrepeatexpansion pages 1-2): Jiaxi Yu, Tongling Liufu, Yilei Zheng, Jin Xu, Lingchao Meng, Wei Zhang, Yun Yuan, Daojun Hong, Nicolas Charlet-Berguerand, Zhaoxia Wang, and Jianwen Deng. Cgg repeat expansion in notch2nlc causes mitochondrial dysfunction and progressive neurodegeneration in drosophila model. Proceedings of the National Academy of Sciences of the United States of America, Oct 2022. URL: https://doi.org/10.1073/pnas.2208649119, doi:10.1073/pnas.2208649119. This article has 57 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02